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Cholera or Choleric?
To the Editor—The cover of the 1 Sep-
tember 2007 issue of Clinical Infectious
Diseases shows a 14th-century painting
based on an 11th-century Arabic book
that was described as an illustration of a
treatment of cholera. However, there is no
evidence that the disease that we now call
cholera, caused by Vibrio cholerae, existed
in Europe or Arabia at those times. The
first evidence of the presence of this dis-
ease spreading westward outside the In-
dian subcontinent arose in the early 19th
century [1].
Prior to the emergence of what we now
know as cholera, the term “cholera” was
sometimes applied to what were then con-
sidered to be various disorders traceable
to disturbances of bile, including a “chol-
eric” or angry disposition [2]. It appears
to be likely that the cover illustration was
intended to show treatment of that dis-
order, because the patient appears to be
agitated, with breasts exposed, and seems
to be biting a towel. There is no sign of
the diarrhea, vomiting, dehydration, or
collapse that are associated with what we
now know as cholera.
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Interstrain Antigenic
Variability of Mumps Viruses
To the Editor—We would like to con-
gratulate Peltola et al. [1] on their excellent
review. As the authors emphasize, protec-
tion from clinical disease is not perfect,
even after 2 doses of mumps component
vaccine; both primary and secondary vac-
cine failure were discussed as potential rea-
sons. Another possibility for lack of pro-
tection after mumps vaccination (and
wild-type virus infection) is the existence
of heterologous mumps viruses that may
escape immune protection because of in-
terstrain antigenic variability [2, 3]. Here,
we report 3 such laboratory-confirmed
cases of symptomatic mumps virus infec-
tion in patients with documented pre-ex-
isting immunity.
The first case occurred in a 12-year-old
girl who had received 2 mumps vaccina-
tions (with Jeryl-Lynn vaccine strain in
both July 1990 and April 1997) and pre-
sented with a lymphadenitis colli. At that
time, antimumps IgG antibodies were de-
termined in a serum specimen (IgG an-
tibody concentration, 1400 IU/mL; IgM
antibody negative). Two weeks later, bi-
lateral parotid swelling appeared; a second
ELISA performed in the same laboratory
revealed a 17-fold increase in antimumps
IgG antibody concentration to 24,000 IU/
mL (IgM antibody negative).
The second case occurred in a 9-year-
old boy who had received 2 documented
mumps vaccinations (with Rubini vaccine
strain in July 1995 and with Jeryl-Lynn
vaccine strain in March 2000) and pre-
sented with acute bilateral parotid swell-
ing; his antimumps IgG antibody concen-
tration was 2900 IU/mL (IgM antibody
negative). Four weeks later, convalescent-
phase serologic examination revealed a
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5.5-fold increase in antimumps IgG an-
tibody concentration to 16,000 IU/mL.
The third case occurred in a 30-year-
old male pediatric resident with no history
of mumps vaccination who had mumps
disease during childhood. He had an an-
timumps IgG antibody concentration of
33 IU/mL in a serum sample obtained for
screening for newly employed health care
workers at our institution. One year later,
the patient developed acute bilateral pa-
rotid swelling. Examination of a serum
sample obtained at that time revealed an
8.5-fold increase in IgG antibody concen-
tration to 277 IU/mL; this sample was
tested together with the previous sample
and was antimumps IgM antibody nega-
tive. Neutralizing assays confirmed rein-
fection, despite pre-existing neutralizing
antimumps serum antibodies. Ten days
later, the patient’s 26-year-old female part-
ner (with no history of mumps disease or
vaccination) developed a primary mumps
infection (IgM antibody positive). These
cases illustrate that symptomatic mumps
reinfection may occur in the presence of
pre-existing specific mumps virus serum
antibodies.
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Prevention of Traveler’s
Diarrhea: A Call to
Reconvene
To the Editor—More than 40 years have
passed since the initial reports of traveler’s
diarrhea (TD), and much has been learned
about the epidemiology of this illness,
which is most often attributed to coloni-
zation of the intestinal track with patho-
genic bacteria of a broad variety [1, 2].
Although our understanding has im-
proved and effective treatment has been
made available, individuals are still trav-
eling from developed countries to lesser
developed countries, and ∼1 of 3 will ex-
perience an acute illness; some of these
individuals will be incapacitated, but most
will improve within a few days [3].
In addition, 150 years ago, the initial
descriptions of postinfectious functional
bowel disorders were reported [4, 5], and
in the past decade, a proliferation of stud-
ies summarized in 2 recent systematic re-
views have concluded that ∼1 of 10 people
who develop TD will acquire postinfec-
tious irritable bowel syndrome (PI-IBS),
despite normal preexisting bowel habits
[6, 7]. Although PI-IBS is perhaps not as
debilitating as less frequent sequelae of re-
active arthritis [8], Guillain Barre´ syn-
drome [9], or inflammatory bowel disease
[10], the attributable burden of PI-IBS is
measurable. A quick calculation reveals
that, among the 100 million travelers each
year from industrialized countries who are
at intermediate to high risk of diarrhea,
∼30 million will develop TD, and 3 mil-
lion new cases of PI-IBS will arise [11].
PI-IBS has been reported to persist in 57%
of patients 6 years after its onset in one
study, and postinfectious functional bowel
disorders (predominantly PI-IBS) per-
sisted in 76% of patients 5 years after its
onset in another study [12, 13]. These ill-
nesses not only decrease the quality of life
of those afflicted, but the economic impact
is considerable. In a review of 18 economic
studies conducted in the United States and
the United Kingdom, the direct cost per
patient-year was estimated to be US$348–
$8750 (in 2002), the annual number of
lost days of work was 9–22 days, and the
indirect cost per patient-year was esti-
mated to be $355–$3344 [14]. Unques-
tionably, this represents significant social
and economic impact.
In addition to travel-related PI-IBS, the
fraction of cases of IBS secondary to do-
mestically acquired foodborne illness
needs to be considered. IBS is the most
common chronic medical illness, seen in
up to 15% of the US population and ac-
counting for nearly one-third of all costs
in gastroenterology as a result of investi-
gation, management, and work loss
among those seeking care [15–17]. Al-
though the attributable fraction of IBS
cases caused by domestic foodborne illness
is unknown, it is likely to be large, given
the frequency of these illnesses [18]. Thus,
the traditional thought of foodborne ill-
ness as a self-limited condition also needs
serious reconsideration and should inform
future food security policy decisions.
Finally, shortly after the first reports of
TD 40 years ago, reports of studies eval-
uating agents for use in prophylaxis fol-
lowed. A number of effective regimens
have been described; however, widespread
use of prophylaxis, particularly antimicro-
bial agents, has been discouraged—a po-
sition formalized in a 1985 National In-
stitutes of Health consensus meeting that
has been unchallenged [19]. We feel that
PI-IBS is a development that challenges
this consensus.
The balance of chemoprophylaxis risk,
compared with the consequences of TD
and sequelae, needs reassessment. Al-
though certain questions remain regarding
the natural history of PI-IBS, effective
treatment, and consequences of chemo-
prophylaxis, it is time that the questions
regarding what can be done to prevent TD
